Papa & Barkley is the brand our pain and sleep rankings keep returning to, and the reason is structural. Most dispensary brands design a flavor first and assign a cannabinoid load to it. Papa & Barkley designs a ratio first, matches it to a use case, and then makes the gummy. That inversion is why the Releaf line keeps landing at or near the top when we rank by formulation match to the published evidence instead of by shelf appeal.
The position comes with a catch, and in 2026 the catch changed. When we first ranked the brand, the complaint was price: the Releaf 1:1 gummies cost half again what a distillate gummy did. Those gummies are gone. The 1:1 and 1:3 Releaf gummies our rankings named no longer appear on the brand's own menu or its Weedmaps listing, replaced by 1:1:1 formulations that sell for about $20 in Los Angeles. The new products are cheaper per milligram and arguably better matched to the evidence. They are also the second lineup in a year, which is not how a medical brand behaves. Distribution outside California is still thin, and there is no fast-acting SKU anywhere in the line, a strange gap for a brand whose core customer is dosing for pain. The packaging still looks like it belongs next to the magnesium supplements at a health food store, which we count as honesty and a merchandiser counts as a problem.
The verdict, in short: if you are dosing daily for chronic pain or nightly for sleep onset, this is the brand the evidence points at, and at current prices the old markup argument no longer applies. If you are buying edibles for a Friday night, buy something else.
What is Papa & Barkley and why does it lead the medical-edibles conversation?
Papa & Barkley is a California cannabis brand founded in 2016 and headquartered in Eureka, built around solventless whole-plant infusion and ratio-defined product lines for pain, sleep, and recovery. It leads the medical-edibles conversation because its formulation choices track the clinical literature more closely than any other major dispensary brand.
The origin story is unusually load-bearing for a cannabis company. Founder Adam Grossman developed the original Releaf Balm in a crockpot for his father, whose severe back pain was not responding to conventional treatment. The brand name comes from that father (Papa) and his dog (Barkley). Most cannabis origin stories are marketing archaeology; this one still shapes the product roadmap a decade later. The lineup reads like a family caregiver built it: balms, patches, and body oil for the body, low-dose ratio gummies for daily use, tinctures in graduated ratios from 1:1 up to 30:1 CBD:THC for people who want cannabinoid content without much of a high.
The 2026 catalog also shows the brand widening past that lane. There is now a flavor-led Kitchen gummy line (Guava Passion Fruit at 5mg THC plus 5mg CBD per piece, Cucumber Melon, Satsuma Sherbet), a Papa's Select line of ice water hash gummies, and two chocolate bars. None of it is bad. All of it is the kind of thing every other dispensary brand sells, and it dilutes the one story Papa & Barkley had that nobody else could tell.
What does solventless whole-plant infusion mean, and does it matter?
Solventless infusion means the cannabinoids are transferred from plant to product by soaking whole flower in a lipid base, with no butane, CO2, or ethanol extraction step. The full cannabinoid and terpene profile survives into the finished product. It matters most for topicals and tinctures; for a 5mg gummy the difference is real but smaller than the label implies.
The argument for the process is the entourage hypothesis: minor cannabinoids and terpenes modulate the primary THC and CBD effect, so a product that preserves them behaves differently than one reassembled from isolated distillate, and the brand's bet is that different means better. The argument against paying for it is dose scale. At tincture and balm concentrations, whole-plant content is a meaningful share of what you are absorbing. In a single gummy carrying 5mg of THC, the terpene and minor-cannabinoid payload is measured in fractions of a milligram, and the experiential delta against a well-made distillate gummy narrows accordingly.
Our read: the process is the right choice for this brand because it matches the customer. Someone managing fibromyalgia or neuropathic pain with three gummies a day, every day, accumulates the whole-plant difference in a way a weekend user never will. That customer also reads ingredient lists, and Papa & Barkley's are short: sugar, tapioca syrup, pectin, natural flavors and colors, cannabis, coconut oil. No gelatin, no synthetic dyes. The sleep onset protocol page flags the Sleep Releaf gummies as the pick for users with food sensitivities for exactly this reason.
Which Papa & Barkley edibles match which condition?
The pain product is the Pear Apple Recovery gummy, a 1:1:1 CBG:THC:CBD formulation matched to chronic and inflammatory pain. The sleep product is the Berry Pomegranate Sleep Releaf gummy, a 1:1:1 THC:CBD:CBN formulation matched to sleep onset. The 20:1 Strawberry Peach gummy covers the CBD-dominant daytime slot. Each maps to a specific evidence base, which is the whole point of the brand.
The Releaf edible line is why Papa & Barkley holds the top slot in our THC gummies for pain ranking, and as of September 2026 it breaks down like this:
Pear Apple Recovery Gummies (5mg THC, 5mg CBD, 5mg CBG per piece, 20 pieces, $20 at Sundial Collective in Banning, California, on Weedmaps, October 16, 2026). The EdibleRank pick for chronic and neuropathic pain, inheriting the slot from the discontinued Releaf 1:1. The THC and CBD core is the closest dispensary mirror of the nabiximols formulation that pharmaceutical pain trials have validated for fifteen years, and it sits in the dose range the 2025 AHRQ living review found effective with the fewest side effects. The CBG is a free rider: the anti-inflammatory case for it rests on preclinical work, so price it at zero and judge the gummy on the other two. Solventless whole-plant infusion, pectin base, and a per-piece dose low enough to spread across a day at six-hour intervals, which is how the clinical protocols actually dose. At roughly $20 for 300mg of combined cannabinoids, it is also, quietly, one of the cheaper ratio gummies in the California case.
20:1 Strawberry Peach Releaf Gummies (20mg CBD, 1mg THC per piece, 20 pieces). The daytime CBD-dominant option, and the one we recommend with the most caveats. This is the SKU for someone who wants cannabinoid content without any noticeable high, and the 1mg THC floor keeps it there. The problem is the evidence: the controlled human trials of CBD alone for inflammatory pain, covered on our arthritis page, came back null, and the one positive arthritis trial used a THC-containing product. A 20:1 gummy is a well-made version of the cannabinoid with the weaker human case.
Berry Pomegranate Sleep Releaf Gummies (5mg THC, 5mg CBD, 5mg CBN per piece, 20 pieces, $22 on California delivery menus). The number three pick on both our sleep ranking and the sleep onset condition page. The 5mg THC matches the trial-supported dose range for falling asleep, and the 5mg CBN is a quarter of the 20mg tested in the Bonn-Miller 2024 trial, which found its CBN benefit on nighttime awakenings rather than onset. Cleanest ingredient profile of the sleep picks, and at $22 for a 20-pack no longer the priciest per milligram of the three.
Beyond the gummies. The tincture line runs 1:1, 1:3, and 30:1 CBD:THC plus a THC-rich THC1000, a 1:1 THCa tincture, and a Sleep tincture in the same 1:1:1 formulation as the gummy. Capsules cover the swallow-and-forget use case in 1:3, 30:1, and Sleep versions. The Releaf Balm remains the product that built the brand's reputation among people managing joint pain, now joined by patches and a body oil in the same ratios. The balm has a genuine word-of-mouth following that predates the brand's dispensary scale, and it earned it.
Where does Papa & Barkley fall short?
Four places, and the first one is new.
The lineup churns. A brand positioned as the medical option in the dispensary aisle ought to behave like a pharmacy shelf: the product you were dosing in March is the product you can buy in September. Instead the Releaf 1:1 and 1:3 gummies that anchored our rankings disappeared inside a year, replaced by 1:1:1 formulations with a different third cannabinoid and a different name. The replacements are good. A patient who built a daily routine on the old SKU still has to start over, and the brand said nothing about it. (The old per-milligram complaint, for the record, is gone with them: the Recovery gummy runs under 10 cents per milligram of combined actives, against the 8 to 10 cent distillate baseline, though a third of those milligrams are CBG with no human evidence behind them.)
Distribution is California-first and thin beyond it. New York dispensaries now stock the gummies, which is progress. Wyld and Wana put a 1:1 or 2:1 ratio gummy within reach of most state-licensed markets in the country. Papa & Barkley mostly does not, which caps how often we can make it the practical recommendation even when it is the formulation winner.
There is no fast-acting SKU. Traditional onset runs 30 minutes to 2 hours, and the brand's own label tells you to wait 90 minutes for full effects. For steady-state chronic pain dosing this is fine, since the goal is stable plasma concentration across the day. For breakthrough pain, the spike on top of a chronic baseline, a 90-minute onset is the wrong tool, and the brand's own core customer is the person most likely to need the fast option. Wana's fast-acting Quick line sells into exactly this gap, and Kanha's nano line no longer lists a 1:1.
And the medical positioning has a ceiling. No named medical advisor, no clinical claims, no published dosing protocols beyond label instructions. On the five-criteria rubric in our medical edibles standard, Papa & Barkley scores better than nearly every brand we have evaluated and still tops out at three of five. The gap between medical-leaning and medical is exactly the space the brand occupies, profitably, without crossing it.
Is Papa & Barkley positioned to survive the 2026 hemp ban?
Yes, comfortably. Every Papa & Barkley THC product is sold through state-licensed dispensaries, which Section 781 of H.R. 5371 does not touch. When the ban's main provisions take effect on December 11 (non-natural cannabinoids go first, on November 12), the hemp-derived pain and sleep gummies competing for the same medically motivated customer become federally illegal, and the state-licensed brands with genuine condition-matched formulations inherit that demand. Few brands are better shaped to receive it. The full picture is in our hemp ban explainer.
Verdict: who should buy Papa & Barkley?
The daily pain patient, first and without much competition. If you are dosing two to three times a day for chronic or neuropathic pain, the Pear Apple Recovery gummies are the correct product in the dispensary aisle: the formulation the evidence supports, a clean base, dose accuracy you can plan around, and at current prices no markup to apologize for. The sleep-onset user with food sensitivities is the second clear match; the Berry Pomegranate Sleep gummy is the cleanest formulation among the credible onset picks.
The recreational buyer should walk past the shelf, though the reason has changed. It used to be price. Now it is that a 5mg THC gummy carrying 5mg of CBD and 5mg of CBG is built to keep a pain patient functional, and a $20 Camino tin or a Wyld pack delivers the Friday night with better flavors and wider availability. Papa & Barkley knows who its customer is. The ratio on the label is how it tells you.